Clinical Trial Results:
A Phase 2, Placebo-Controlled, Randomized, Double-Blind, Parallel Arm, Dose Ranging
Study to Evaluate Safety and Efficacy of Apixaban In Patients with a Recent Acute
Coronary Syndrome.
Revised Protocol 01 incorporating Amendment 03
And Parmacogenetics Blood Sample Amendment 01 dated 17-Feb-2006
Revised Protocol 02 incorporating Amendment 04 and Admin Letter 01
Summary
|
|
EudraCT number |
2005-004338-42 |
Trial protocol |
SE NL GB ES BE DE DK AT IT |
Global completion date |
27 May 2008
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
08 Dec 2016
|
First version publication date |
08 Dec 2016
|
Other versions |
|
Summary report(s) |
CV185-023_Synopses |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.